Idorsia Ltd
SIX:IDIA
Intrinsic Value
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. [ Read More ]
The intrinsic value of one IDIA stock under the Base Case scenario is 8.79 CHF. Compared to the current market price of 1.9 CHF, Idorsia Ltd is Undervalued by 78%.
Valuation Backtest
Idorsia Ltd
Run backtest to discover the historical profit from buying and selling IDIA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Idorsia Ltd
Current Assets | 376.2m |
Cash & Short-Term Investments | 266.1m |
Receivables | 26.4m |
Other Current Assets | 83.7m |
Non-Current Assets | 276.9m |
PP&E | 212.3m |
Intangibles | 6.1m |
Other Non-Current Assets | 58.5m |
Current Liabilities | 311.1m |
Accounts Payable | 18.4m |
Accrued Liabilities | 65.2m |
Other Current Liabilities | 227.5m |
Non-Current Liabilities | 1.2B |
Long-Term Debt | 930.8m |
Other Non-Current Liabilities | 242.2m |
Earnings Waterfall
Idorsia Ltd
Revenue
|
184.7m
CHF
|
Cost of Revenue
|
-9.4m
CHF
|
Gross Profit
|
175.3m
CHF
|
Operating Expenses
|
-796m
CHF
|
Operating Income
|
-620.7m
CHF
|
Other Expenses
|
246.7m
CHF
|
Net Income
|
-374.1m
CHF
|
Free Cash Flow Analysis
Idorsia Ltd
IDIA Profitability Score
Profitability Due Diligence
Idorsia Ltd's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Idorsia Ltd's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
IDIA Solvency Score
Solvency Due Diligence
Idorsia Ltd's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
Idorsia Ltd's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IDIA Price Targets Summary
Idorsia Ltd
According to Wall Street analysts, the average 1-year price target for IDIA is 2.15 CHF with a low forecast of 1.01 CHF and a high forecast of 4.2 CHF.
Shareholder Return
IDIA Price
Idorsia Ltd
Average Annual Return | -3.21% |
Standard Deviation of Annual Returns | 39.35% |
Max Drawdown | -96% |
Market Capitalization | 339.3m CHF |
Shares Outstanding | 188 573 517 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one IDIA stock under the Base Case scenario is 8.79 CHF.
Compared to the current market price of 1.9 CHF, Idorsia Ltd is Undervalued by 78%.